img

Global and United States Non-Benzodiazepines Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Non-Benzodiazepines Market Report & Forecast 2024-2034

Non-benzodiazepines are a relatively new class of hypnotics
Market Analysis and InsightsGlobal and United States Non-Benzodiazepines Market
This report focuses on global and United States Non-Benzodiazepines market, also covers the segmentation data of other regions in regional level and county level.
The global Non-Benzodiazepines revenue was US$ 650 million in 2022 and is forecast to a readjusted size of US$ 1436.9 million by 2034 with a CAGR of 12.0% during the forecast period (2024-2034).
In United States the Non-Benzodiazepines revenue is expected to grow from US$ million in 2022 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Non-Benzodiazepines include Pfizer, Teva Pharmaceuticals, Torrent Pharma, Accord Healthcare, Akorn, Apotex, Fresenius Kabi, Hikma and Mylan, etc. The global five biggest players hold a share of % in 2022.
Global Non-Benzodiazepines Scope and Market Size
Non-Benzodiazepines market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Non-Benzodiazepines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2024-2034.
For United States market, this report focuses on the Non-Benzodiazepines market size by players, by Type and by Application, for the period 2024-2034. The key players include the global and local players, which play important roles in United States.



By Company


Pfizer
Teva Pharmaceuticals
Torrent Pharma
Accord Healthcare
Akorn
Apotex
Fresenius Kabi
Hikma
Mylan
Par Pharmaceuticals
Sandoz
Sun Pharma
WG Critical Care
Athenex
Chenxin Pharmaceutical
Huatai Chenguang Pharmaceutical
Segment by Type
Dexmedetomidine
Zolpidem
Eszopiclone
Zopiclone
other

Segment by Application


Hospital
Clinic
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Non-Benzodiazepines definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Non-Benzodiazepines companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Non-Benzodiazepines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-Benzodiazepines sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Non-Benzodiazepines Product Introduction
1.2 Global Non-Benzodiazepines Outlook 2024 VS 2022 VS 2034
1.2.1 Global Non-Benzodiazepines Sales in US$ Million for the Year 2024-2034
1.2.2 Global Non-Benzodiazepines Sales in Volume for the Year 2024-2034
1.3 United States Non-Benzodiazepines Outlook 2024 VS 2022 VS 2034
1.3.1 United States Non-Benzodiazepines Sales in US$ Million for the Year 2024-2034
1.3.2 United States Non-Benzodiazepines Sales in Volume for the Year 2024-2034
1.4 Non-Benzodiazepines Market Size, United States VS Global, 2024 VS 2022 VS 2034
1.4.1 The Market Share of United States Non-Benzodiazepines in Global, 2024 VS 2022 VS 2034
1.4.2 The Growth Rate of Non-Benzodiazepines Market Size, United States VS Global, 2024 VS 2022 VS 2034
1.5 Non-Benzodiazepines Market Dynamics
1.5.1 Non-Benzodiazepines Industry Trends
1.5.2 Non-Benzodiazepines Market Drivers
1.5.3 Non-Benzodiazepines Market Challenges
1.5.4 Non-Benzodiazepines Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Non-Benzodiazepines by Type
2.1 Non-Benzodiazepines Market Segment by Type
2.1.1 Dexmedetomidine
2.1.2 Zolpidem
2.1.3 Eszopiclone
2.1.4 Zopiclone
2.1.5 other
2.2 Global Non-Benzodiazepines Market Size by Type
2.2.1 Global Non-Benzodiazepines Sales in Value, by Type (2024, 2022 & 2034)
2.2.2 Global Non-Benzodiazepines Sales in Volume, by Type (2024, 2022 & 2034)
2.2.3 Global Non-Benzodiazepines Average Selling Price (ASP) by Type (2024, 2022 & 2034)
2.3 United States Non-Benzodiazepines Market Size by Type
2.3.1 United States Non-Benzodiazepines Sales in Value, by Type (2024, 2022 & 2034)
2.3.2 United States Non-Benzodiazepines Sales in Volume, by Type (2024, 2022 & 2034)
2.3.3 United States Non-Benzodiazepines Average Selling Price (ASP) by Type (2024, 2022 & 2034)
3 Non-Benzodiazepines by Application
3.1 Non-Benzodiazepines Market Segment by Application
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Other
3.2 Global Non-Benzodiazepines Market Size by Application
3.2.1 Global Non-Benzodiazepines Sales in Value, by Application (2024, 2022 & 2034)
3.2.2 Global Non-Benzodiazepines Sales in Volume, by Application (2024, 2022 & 2034)
3.3.3 Global Non-Benzodiazepines Average Selling Price (ASP) by Application (2024, 2022 & 2034)
3.3 United States Non-Benzodiazepines Market Size by Application
3.3.1 United States Non-Benzodiazepines Sales in Value, by Application (2024, 2022 & 2034)
3.3.2 United States Non-Benzodiazepines Sales in Volume, by Application (2024, 2022 & 2034)
3.3.3 United States Non-Benzodiazepines Average Selling Price (ASP) by Application (2024, 2022 & 2034)
4 Global Non-Benzodiazepines Competitor Landscape by Company
4.1 Global Non-Benzodiazepines Market Size by Company
4.1.1 Global Key Manufacturers of Non-Benzodiazepines, Ranked by Revenue (2022)
4.1.2 Global Non-Benzodiazepines Revenue by Manufacturer (2024-2024)
4.1.3 Global Non-Benzodiazepines Sales by Manufacturer (2024-2024)
4.1.4 Global Non-Benzodiazepines Price by Manufacturer (2024-2024)
4.2 Global Non-Benzodiazepines Concentration Ratio (CR)
4.2.1 Non-Benzodiazepines Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Non-Benzodiazepines in 2022
4.2.3 Global Non-Benzodiazepines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Non-Benzodiazepines, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Non-Benzodiazepines, Product Offered and Application
4.5 Global Key Manufacturers of Non-Benzodiazepines, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 United States Non-Benzodiazepines Market Size by Company
4.7.1 Key Players of Non-Benzodiazepines in United States, Ranked by Revenue (2022)
4.7.2 United States Non-Benzodiazepines Revenue by Players (2024-2024)
4.7.3 United States Non-Benzodiazepines Sales by Players (2024-2024)
5 Global Non-Benzodiazepines Market Size by Region
5.1 Global Non-Benzodiazepines Market Size by Region: 2024 VS 2022 VS 2034
5.2 Global Non-Benzodiazepines Market Size in Volume by Region (2024-2034)
5.2.1 Global Non-Benzodiazepines Sales in Volume by Region: 2024-2024
5.2.2 Global Non-Benzodiazepines Sales in Volume Forecast by Region (2024-2034)
5.3 Global Non-Benzodiazepines Market Size in Value by Region (2024-2034)
5.3.1 Global Non-Benzodiazepines Sales in Value by Region: 2024-2024
5.3.2 Global Non-Benzodiazepines Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas Non-Benzodiazepines Market Size YoY Growth 2024-2034
6.2 Americas Non-Benzodiazepines Sales in Volume, by Type (2024, 2022 & 2034)
6.3 Americas Non-Benzodiazepines Sales in Volume, by Application (2024, 2022 & 2034)
6.4 Americas Non-Benzodiazepines Market Facts & Figures by Country (2024, 2022 & 2034)
6.4.1 Americas Non-Benzodiazepines Sales in Value by Country (2024, 2022 & 2034)
6.4.2 Americas Non-Benzodiazepines Sales in Volume by Country (2024, 2022 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Non-Benzodiazepines Market Size YoY Growth 2024-2034
7.2 EMEA Non-Benzodiazepines Sales in Volume, by Type (2024, 2022 & 2034)
7.3 EMEA Non-Benzodiazepines Sales in Volume, by Application (2024, 2022 & 2034)
7.4 EMEA Non-Benzodiazepines Market Facts & Figures by Country (2024, 2022 & 2034)
7.4.1 EMEA Non-Benzodiazepines Sales in Value by Country (2024, 2022 & 2034)
7.4.2 EMEA Non-Benzodiazepines Sales in Volume by Country (2024, 2022 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Non-Benzodiazepines Market Size YoY Growth 2024-2034
8.2 China Non-Benzodiazepines Sales in Volume, by Type (2024, 2022 & 2034)
8.3 China Non-Benzodiazepines Sales in Volume, by Application (2024, 2022 & 2034)
9 APAC
9.1 APAC Non-Benzodiazepines Market Size YoY Growth 2024-2034
9.2 APAC Non-Benzodiazepines Sales in Volume, by Type (2024, 2022 & 2034)
9.3 APAC Non-Benzodiazepines Sales in Volume, by Application (2024, 2022 & 2034)
9.4 APAC Non-Benzodiazepines Market Facts & Figures by Region (2024, 2022 & 2034)
9.4.1 APAC Non-Benzodiazepines Sales in Value by Region (2024, 2022 & 2034)
9.4.2 APAC Non-Benzodiazepines Sales in Volume by Region (2024, 2022 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Description and Business Overview
10.1.3 Pfizer Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.1.4 Pfizer Non-Benzodiazepines Products Offered
10.1.5 Pfizer Recent Development
10.2 Teva Pharmaceuticals
10.2.1 Teva Pharmaceuticals Company Information
10.2.2 Teva Pharmaceuticals Description and Business Overview
10.2.3 Teva Pharmaceuticals Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.2.4 Teva Pharmaceuticals Non-Benzodiazepines Products Offered
10.2.5 Teva Pharmaceuticals Recent Development
10.3 Torrent Pharma
10.3.1 Torrent Pharma Company Information
10.3.2 Torrent Pharma Description and Business Overview
10.3.3 Torrent Pharma Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.3.4 Torrent Pharma Non-Benzodiazepines Products Offered
10.3.5 Torrent Pharma Recent Development
10.4 Accord Healthcare
10.4.1 Accord Healthcare Company Information
10.4.2 Accord Healthcare Description and Business Overview
10.4.3 Accord Healthcare Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.4.4 Accord Healthcare Non-Benzodiazepines Products Offered
10.4.5 Accord Healthcare Recent Development
10.5 Akorn
10.5.1 Akorn Company Information
10.5.2 Akorn Description and Business Overview
10.5.3 Akorn Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.5.4 Akorn Non-Benzodiazepines Products Offered
10.5.5 Akorn Recent Development
10.6 Apotex
10.6.1 Apotex Company Information
10.6.2 Apotex Description and Business Overview
10.6.3 Apotex Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.6.4 Apotex Non-Benzodiazepines Products Offered
10.6.5 Apotex Recent Development
10.7 Fresenius Kabi
10.7.1 Fresenius Kabi Company Information
10.7.2 Fresenius Kabi Description and Business Overview
10.7.3 Fresenius Kabi Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.7.4 Fresenius Kabi Non-Benzodiazepines Products Offered
10.7.5 Fresenius Kabi Recent Development
10.8 Hikma
10.8.1 Hikma Company Information
10.8.2 Hikma Description and Business Overview
10.8.3 Hikma Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.8.4 Hikma Non-Benzodiazepines Products Offered
10.8.5 Hikma Recent Development
10.9 Mylan
10.9.1 Mylan Company Information
10.9.2 Mylan Description and Business Overview
10.9.3 Mylan Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.9.4 Mylan Non-Benzodiazepines Products Offered
10.9.5 Mylan Recent Development
10.10 Par Pharmaceuticals
10.10.1 Par Pharmaceuticals Company Information
10.10.2 Par Pharmaceuticals Description and Business Overview
10.10.3 Par Pharmaceuticals Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.10.4 Par Pharmaceuticals Non-Benzodiazepines Products Offered
10.10.5 Par Pharmaceuticals Recent Development
10.11 Sandoz
10.11.1 Sandoz Company Information
10.11.2 Sandoz Description and Business Overview
10.11.3 Sandoz Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.11.4 Sandoz Non-Benzodiazepines Products Offered
10.11.5 Sandoz Recent Development
10.12 Sun Pharma
10.12.1 Sun Pharma Company Information
10.12.2 Sun Pharma Description and Business Overview
10.12.3 Sun Pharma Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.12.4 Sun Pharma Non-Benzodiazepines Products Offered
10.12.5 Sun Pharma Recent Development
10.13 WG Critical Care
10.13.1 WG Critical Care Company Information
10.13.2 WG Critical Care Description and Business Overview
10.13.3 WG Critical Care Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.13.4 WG Critical Care Non-Benzodiazepines Products Offered
10.13.5 WG Critical Care Recent Development
10.14 Athenex
10.14.1 Athenex Company Information
10.14.2 Athenex Description and Business Overview
10.14.3 Athenex Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.14.4 Athenex Non-Benzodiazepines Products Offered
10.14.5 Athenex Recent Development
10.15 Chenxin Pharmaceutical
10.15.1 Chenxin Pharmaceutical Company Information
10.15.2 Chenxin Pharmaceutical Description and Business Overview
10.15.3 Chenxin Pharmaceutical Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.15.4 Chenxin Pharmaceutical Non-Benzodiazepines Products Offered
10.15.5 Chenxin Pharmaceutical Recent Development
10.16 Huatai Chenguang Pharmaceutical
10.16.1 Huatai Chenguang Pharmaceutical Company Information
10.16.2 Huatai Chenguang Pharmaceutical Description and Business Overview
10.16.3 Huatai Chenguang Pharmaceutical Non-Benzodiazepines Sales, Revenue and Gross Margin (2024-2024)
10.16.4 Huatai Chenguang Pharmaceutical Non-Benzodiazepines Products Offered
10.16.5 Huatai Chenguang Pharmaceutical Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Non-Benzodiazepines Industry Chain Analysis
11.2 Non-Benzodiazepines Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Non-Benzodiazepines Production Mode & Process
11.4 Non-Benzodiazepines Sales and Marketing
11.4.1 Non-Benzodiazepines Sales Channels
11.4.2 Non-Benzodiazepines Distributors
11.5 Non-Benzodiazepines Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Non-Benzodiazepines CAGR in Value, United States VS Global, 2024 VS 2022 VS 2034
Table 2. Non-Benzodiazepines Market Trends
Table 3. Non-Benzodiazepines Market Drivers
Table 4. Non-Benzodiazepines Market Challenges
Table 5. Non-Benzodiazepines Market Restraints
Table 6. Global Non-Benzodiazepines Sales Growth Rate (CAGR) by Type: 2024 VS 2022 VS 2034 (US$ Million)
Table 7. United States Non-Benzodiazepines Sales Growth Rate (CAGR) by Type: 2024 VS 2022 VS 2034 (US$ Million)
Table 8. Global Non-Benzodiazepines Sales Growth Rate (CAGR) by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 9. United States Non-Benzodiazepines Sales Growth Rate (CAGR) by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of Non-Benzodiazepines, Ranked by Revenue (2022) & (US$ Million)
Table 11. Global Non-Benzodiazepines Revenue by Manufacturer, (US$ Million), 2024-2024
Table 12. Global Non-Benzodiazepines Revenue Share by Manufacturer, 2024-2024
Table 13. Global Non-Benzodiazepines Sales by Manufacturer, (K Units), 2024-2024
Table 14. Global Non-Benzodiazepines Sales Share by Manufacturer, 2024-2024
Table 15. Global Non-Benzodiazepines Price by Manufacturer (2024-2024) & (US$/Unit)
Table 16. Global Non-Benzodiazepines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Non-Benzodiazepines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Benzodiazepines as of 2022)
Table 18. Global Key Manufacturers of Non-Benzodiazepines, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Non-Benzodiazepines, Product Offered and Application
Table 20. Global Key Manufacturers of Non-Benzodiazepines, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Non-Benzodiazepines in United States, Ranked by Revenue (2022) & (US$ million)
Table 23. United States Non-Benzodiazepines Revenue by Players, (US$ Million), (2024-2024)
Table 24. United States Non-Benzodiazepines Revenue Share by Players, (2024-2024)
Table 25. United States Non-Benzodiazepines Sales by Players, (K Units), (2024-2024)
Table 26. United States Non-Benzodiazepines Sales Share by Players, (2024-2024)
Table 27. Global Non-Benzodiazepines Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 28. Global Non-Benzodiazepines Sales in Volume by Region (2024-2024) & (K Units)
Table 29. Global Non-Benzodiazepines Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global Non-Benzodiazepines Sales in Value by Region (2024-2024) & (US$ Million)
Table 31. Global Non-Benzodiazepines Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas Non-Benzodiazepines Market Size Growth Rate (CAGR) by Country (US$ Million): 2024 VS 2022 VS 2034
Table 33. Americas Non-Benzodiazepines Sales in Value by Country (2024-2024) & (US$ Million)
Table 34. Americas Non-Benzodiazepines Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas Non-Benzodiazepines Sales in Volume by Country (2024-2024) & (K Units)
Table 36. Americas Non-Benzodiazepines Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA Non-Benzodiazepines Market Size Growth Rate (CAGR) by Country (US$ Million): 2024 VS 2022 VS 2034
Table 38. EMEA Non-Benzodiazepines Sales in Value by Country (2024-2024) & (US$ Million)
Table 39. EMEA Non-Benzodiazepines Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA Non-Benzodiazepines Sales in Volume by Country (2024-2024) & (K Units)
Table 41. EMEA Non-Benzodiazepines Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC Non-Benzodiazepines Market Size Growth Rate (CAGR) by Country (US$ Million): 2024 VS 2022 VS 2034
Table 43. APAC Non-Benzodiazepines Sales in Value by Country (2024-2024) & (US$ Million)
Table 44. APAC Non-Benzodiazepines Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC Non-Benzodiazepines Sales in Volume by Country (2024-2024) & (K Units)
Table 46. APAC Non-Benzodiazepines Sales in Volume by Country (2024-2034) & (K Units)
Table 47. Pfizer Company Information
Table 48. Pfizer Description and Business Overview
Table 49. Pfizer Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 50. Pfizer Non-Benzodiazepines Product
Table 51. Pfizer Recent Development
Table 52. Teva Pharmaceuticals Company Information
Table 53. Teva Pharmaceuticals Description and Business Overview
Table 54. Teva Pharmaceuticals Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 55. Teva Pharmaceuticals Non-Benzodiazepines Product
Table 56. Teva Pharmaceuticals Recent Development
Table 57. Torrent Pharma Company Information
Table 58. Torrent Pharma Description and Business Overview
Table 59. Torrent Pharma Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 60. Torrent Pharma Non-Benzodiazepines Product
Table 61. Torrent Pharma Recent Development
Table 62. Accord Healthcare Company Information
Table 63. Accord Healthcare Description and Business Overview
Table 64. Accord Healthcare Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 65. Accord Healthcare Non-Benzodiazepines Product
Table 66. Accord Healthcare Recent Development
Table 67. Akorn Company Information
Table 68. Akorn Description and Business Overview
Table 69. Akorn Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 70. Akorn Non-Benzodiazepines Product
Table 71. Akorn Recent Development
Table 72. Apotex Company Information
Table 73. Apotex Description and Business Overview
Table 74. Apotex Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 75. Apotex Non-Benzodiazepines Product
Table 76. Apotex Recent Development
Table 77. Fresenius Kabi Company Information
Table 78. Fresenius Kabi Description and Business Overview
Table 79. Fresenius Kabi Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 80. Fresenius Kabi Non-Benzodiazepines Product
Table 81. Fresenius Kabi Recent Development
Table 82. Hikma Company Information
Table 83. Hikma Description and Business Overview
Table 84. Hikma Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 85. Hikma Non-Benzodiazepines Product
Table 86. Hikma Recent Development
Table 87. Mylan Company Information
Table 88. Mylan Description and Business Overview
Table 89. Mylan Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 90. Mylan Non-Benzodiazepines Product
Table 91. Mylan Recent Development
Table 92. Par Pharmaceuticals Company Information
Table 93. Par Pharmaceuticals Description and Business Overview
Table 94. Par Pharmaceuticals Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 95. Par Pharmaceuticals Non-Benzodiazepines Product
Table 96. Par Pharmaceuticals Recent Development
Table 97. Sandoz Company Information
Table 98. Sandoz Description and Business Overview
Table 99. Sandoz Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 100. Sandoz Non-Benzodiazepines Product
Table 101. Sandoz Recent Development
Table 102. Sun Pharma Company Information
Table 103. Sun Pharma Description and Business Overview
Table 104. Sun Pharma Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 105. Sun Pharma Non-Benzodiazepines Product
Table 106. Sun Pharma Recent Development
Table 107. WG Critical Care Company Information
Table 108. WG Critical Care Description and Business Overview
Table 109. WG Critical Care Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 110. WG Critical Care Non-Benzodiazepines Product
Table 111. WG Critical Care Recent Development
Table 112. Athenex Company Information
Table 113. Athenex Description and Business Overview
Table 114. Athenex Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 115. Athenex Non-Benzodiazepines Product
Table 116. Athenex Recent Development
Table 117. Chenxin Pharmaceutical Company Information
Table 118. Chenxin Pharmaceutical Description and Business Overview
Table 119. Chenxin Pharmaceutical Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 120. Chenxin Pharmaceutical Non-Benzodiazepines Product
Table 121. Chenxin Pharmaceutical Recent Development
Table 122. Huatai Chenguang Pharmaceutical Company Information
Table 123. Huatai Chenguang Pharmaceutical Description and Business Overview
Table 124. Huatai Chenguang Pharmaceutical Non-Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 125. Huatai Chenguang Pharmaceutical Non-Benzodiazepines Product
Table 126. Huatai Chenguang Pharmaceutical Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Non-Benzodiazepines Customers List
Table 130. Non-Benzodiazepines Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Non-Benzodiazepines Product Picture
Figure 2. Global Non-Benzodiazepines Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Non-Benzodiazepines Market Size 2024-2034 (US$ Million)
Figure 4. Global Non-Benzodiazepines Sales 2024-2034 (K Units)
Figure 5. United States Non-Benzodiazepines Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 6. United States Non-Benzodiazepines Market Size 2024-2034 (US$ Million)
Figure 7. United States Non-Benzodiazepines Sales 2024-2034 (K Units)
Figure 8. United States Non-Benzodiazepines Market Share in Global, in Value (US$ Million) 2024-2034
Figure 9. United States Non-Benzodiazepines Market Share in Global, in Volume (K Units) 2024-2034
Figure 10. Non-Benzodiazepines Report Years Considered
Figure 11. Product Picture of Dexmedetomidine
Figure 12. Product Picture of Zolpidem
Figure 13. Product Picture of Eszopiclone
Figure 14. Product Picture of Zopiclone
Figure 15. Product Picture of other
Figure 16. Global Non-Benzodiazepines Market Share by Type in 2022 & 2034
Figure 17. Global Non-Benzodiazepines Sales in Value by Type (2024-2034) & (US$ Million)
Figure 18. Global Non-Benzodiazepines Sales Market Share in Value by Type (2024-2034)
Figure 19. Global Non-Benzodiazepines Sales by Type (2024-2034) & (K Units)
Figure 20. Global Non-Benzodiazepines Sales Market Share in Volume by Type (2024-2034)
Figure 21. Global Non-Benzodiazepines Price by Type (2024-2034) & (US$/Unit)
Figure 22. United States Non-Benzodiazepines Market Share by Type in 2022 & 2034
Figure 23. United States Non-Benzodiazepines Sales in Value by Type (2024-2034) & (US$ Million)
Figure 24. United States Non-Benzodiazepines Sales Market Share in Value by Type (2024-2034)
Figure 25. United States Non-Benzodiazepines Sales by Type (2024-2034) & (K Units)
Figure 26. United States Non-Benzodiazepines Sales Market Share in Volume by Type (2024-2034)
Figure 27. United States Non-Benzodiazepines Price by Type (2024-2034) & (US$/Unit)
Figure 28. Product Picture of Hospital
Figure 29. Product Picture of Clinic
Figure 30. Product Picture of Other
Figure 31. Global Non-Benzodiazepines Market Share by Application in 2022 & 2034
Figure 32. Global Non-Benzodiazepines Sales in Value by Application (2024-2034) & (US$ Million)
Figure 33. Global Non-Benzodiazepines Sales Market Share in Value by Application (2024-2034)
Figure 34. Global Non-Benzodiazepines Sales by Application (2024-2034) & (K Units)
Figure 35. Global Non-Benzodiazepines Sales Market Share in Volume by Application (2024-2034)
Figure 36. Global Non-Benzodiazepines Price by Application (2024-2034) & (US$/Unit)
Figure 37. United States Non-Benzodiazepines Market Share by Application in 2022 & 2034
Figure 38. United States Non-Benzodiazepines Sales in Value by Application (2024-2034) & (US$ Million)
Figure 39. United States Non-Benzodiazepines Sales Market Share in Value by Application (2024-2034)
Figure 40. United States Non-Benzodiazepines Sales by Application (2024-2034) & (K Units)
Figure 41. United States Non-Benzodiazepines Sales Market Share in Volume by Application (2024-2034)
Figure 42. United States Non-Benzodiazepines Price by Application (2024-2034) & (US$/Unit)
Figure 43. Americas Non-Benzodiazepines Sales in Volume Growth Rate 2024-2034 (K Units)
Figure 44. Americas Non-Benzodiazepines Sales in Value Growth Rate 2024-2034 (US$ Million)
Figure 45. Americas Non-Benzodiazepines Sales by Type (2024-2034) & (K Units)
Figure 46. Americas Non-Benzodiazepines Sales Market Share in Volume by Type (2024-2034)
Figure 47. Americas Non-Benzodiazepines Sales by Application (2024-2034) & (K Units)
Figure 48. Americas Non-Benzodiazepines Sales Market Share in Volume by Application (2024-2034)
Figure 49. United States Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 50. Canada Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 51. Mexico Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 52. Brazil Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 53. EMEA Non-Benzodiazepines Sales in Volume Growth Rate 2024-2034 (K Units)
Figure 54. EMEA Non-Benzodiazepines Sales in Value Growth Rate 2024-2034 (US$ Million)
Figure 55. EMEA Non-Benzodiazepines Sales by Type (2024-2034) & (K Units)
Figure 56. EMEA Non-Benzodiazepines Sales Market Share in Volume by Type (2024-2034)
Figure 57. EMEA Non-Benzodiazepines Sales by Application (2024-2034) & (K Units)
Figure 58. EMEA Non-Benzodiazepines Sales Market Share in Volume by Application (2024-2034)
Figure 59. Europe Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 60. Middle East Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 61. Africa Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 62. China Non-Benzodiazepines Sales in Volume Growth Rate 2024-2034 (K Units)
Figure 63. China Non-Benzodiazepines Sales in Value Growth Rate 2024-2034 (US$ Million)
Figure 64. China Non-Benzodiazepines Sales by Type (2024-2034) & (K Units)
Figure 65. China Non-Benzodiazepines Sales Market Share in Volume by Type (2024-2034)
Figure 66. China Non-Benzodiazepines Sales by Application (2024-2034) & (K Units)
Figure 67. China Non-Benzodiazepines Sales Market Share in Volume by Application (2024-2034)
Figure 68. APAC Non-Benzodiazepines Sales in Volume Growth Rate 2024-2034 (K Units)
Figure 69. APAC Non-Benzodiazepines Sales in Value Growth Rate 2024-2034 (US$ Million)
Figure 70. APAC Non-Benzodiazepines Sales by Type (2024-2034) & (K Units)
Figure 71. APAC Non-Benzodiazepines Sales Market Share in Volume by Type (2024-2034)
Figure 72. APAC Non-Benzodiazepines Sales by Application (2024-2034) & (K Units)
Figure 73. APAC Non-Benzodiazepines Sales Market Share in Volume by Application (2024-2034)
Figure 74. Japan Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 75. South Korea Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 76. China Taiwan Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 77. Southeast Asia Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 78. India Non-Benzodiazepines Sales in Value Growth Rate (2024-2034) & (US$ Million)
Figure 79. Non-Benzodiazepines Value Chain
Figure 80. Non-Benzodiazepines Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed